Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23163065 | 0.86 | CA2 (0.40) | CA2CA1 | |
| SCHEMBL780399 | 0.81 | CA2 (0.42) | CA2CA1 | |
| SCHEMBL1032931 | 0.80 | CA2 (0.47) | CA2CA1 | |
| SCHEMBL116723 | 0.78 | CA2 (0.43) | CA2CA1 | |
| SCHEMBL15665290 | 0.77 | CA2 (0.40) | CA2CA1 | |
| SCHEMBL20553030 | 0.77 | CA1 (0.34) | CA2CA1 | |
| SCHEMBL777006 | 0.76 | CA2 (0.48) | CA2CA1 | |
| SCHEMBL3242894 | 0.76 | CA2 (0.36) | CA2CA1 | |
| SCHEMBL17643054 | 0.76 | CA2 (0.39) | CA2CA1 | |
| SCHEMBL4224009 | 0.75 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110110890-A1 | Novel Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110110890-A1 | Novel Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2009134616-A2 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| EP-0966443-B1 | HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR | PFIZER (US) | 2009-01-28 | — | — | EP | disclosed |
| WO-2004039375-A1 | METHODS OF USING CCR1 ANTAGONISTS AS IMMUNOMODULATORY AGENTS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20040087571-A1 | Methods of using CCR1 antagonists as immunomodulatory agents | PFIZER INC | 2004-05-06 | — | — | US | disclosed |
| WO-2003013526-A1 | ANTICOAGULANT COMPOUNDS | MERCK & CO. INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| US-20020198207-A1 | Novel Hexanoic acid derivatives | KATH JOHN CHARLES (US) | 2002-12-26 | — | — | US | disclosed |
| US-6403587-B1 | AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND | PFIZER INC. | 2002-06-11 | — | — | US | disclosed |
| CN-1248968-A | Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-alpha binding to its CCRI receptor | PFIZER (US) | 2000-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HDGF | CA2 4358/4885CA1 4719/4885 |
| US-20040087571-A1 | Methods of using CCR1 antagonists as immunomodulatory agents | CCR1, CCR3, CCRL2 | CA2 1513/4885CA1 1852/4885 |
| US-20020198207-A1 | Novel Hexanoic acid derivatives | HCAR3, HCAR1, FFAR1 | CA2 3507/4885CA1 3095/4885 |
| US-20110110890-A1 | Novel Inhibitors of Hepatitis C Virus Replication | HAVCR2, EIF2AK2, HCCS | CA2 4545/4885CA1 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.